National Center for Scientific Research (CNIC)

Pharmaceutical medical industry
25 Ave and 158 No. 15202. Cubanacan. Playa. Havana, Cuba
Ave. 25
Postal code
5372152183, Ext 502; 53 72080948 ; 5372730167
Contact person's name
Rafael Gámez Menéndez (Marketing and Business Development Director)
Short description of the company
The National Center for Scientific Research (CNIC) was created on July 1, 1965.
Nowadays, it is a company that integrates the Group of Biotechnological and Pharmaceutical Industries (BioCubaFarma) of the Republic of Cuba, dedicated to scientific research, production and marketing about pharmaceutical products.
Subject-matters of the institution:
Research and Development of products obtained from natural resources;
Development of vaccines and modified antigens; ozonized and cosmetic oils;
Ozone generator equipments for medical treatment or water disinfection procedures for human consumption and industrial uses;
Medical equipment for microbiological diagnosis, culture media and antibiogram strips;
Specialized technical scientific services
Company`s description
Products on the market:
  • POLICOSANOL 5mg, 10 mg, 20 mg (Ateromixol®; PPG®, DUPLA, MERCOL): Policosanol is purified from sugar cane wax,containing a mixture of 8 higher aliphatic alcohols (≥90%). Effects: Lowers serum levels of LDL-C and total colesterol; Increases serum levels of HDL-C and its functionality; Has Antioxidant effects; Inhibits platelet aggregation; Help to relief intermittent claudication, a symptom of Peripheral Arterial Disease; In patients with recent Ischemic Stroke, improves Neurological recovery and seems to prevent recurrence of events, when is combined with Acetyl Salicylic Acid; Improves general and vascular health, preventing events of this type and complications that appear in atherosclerotic disease; Has a very good safety and tolerability.
  • Vasoactol® 6 mg: A food supplement to complete the daily diet of people when they have been undergone to special effort situations and debilitating circumstances, as happen in middle and third age individuals and / or athletes. This product increases physical performance in elderly and produces beneficial effects on their general health, since third age individuals often suffer dysfunctions resulting from alterations in the physiological balance.
  • Abexol 50 mg®: Nutritional supplements increases antioxidant response of the organism, protecting against oxidative stress, which accelerates aging and its physio- pathological associated processes. In addition, Abexol prevents damage of gastric mucosa induced by oxidative agents, exerting a moderate cytoprotective effect at this level. It ameliorates symptoms of pain, stickiness and help to have functional joints, in patients with osteoarthritis.
  • Prevenox 5 mg®: Nutritional supplements It reduces the impact of oxidative stress that occurs during aging, mainly aimed at people of middle age and elderly, including post-menopausal women. This product reduces serum total cholesterol and LDL-c, prevents their oxidation, and in this way the development of osteoporosis, taking into account the role of oxidized lipids and dyslipidemia on bone metabolism. Then, Prevenox is effective in preventing decreases of the bone-mineral density, which use to occur in physiological, therapeutic or post-surgical menopause. As consequence, such event is followed with a high incidence of fractures in these patients, affecting the quality of life and the real life.
  • Palmex: Nutritional supplements It is recommended in the treatment of benign prostatic hyperplasia. It is an effective antioxidant and scavenger that helps to protect against the effects of free radicals, increasing the antioxidant response of the organism. These results have been demonstrated in experimental and clinical studies, being observed in plasma, liver, brain, and prostate, among other tissues. Clinical trials have been conducted on patients with Benign Prostatic Hyperplasia. Results obtained have shown a significant reduction of lower urinary tract symptoms in men with Benign Prostatic Hyperplasia.
  • Ozonized sunflower oil soap: Specifically, it is indicated for hygiene and daily care of the skin, to smooth dry skin and act as germicide in the treatment of infections caused by microorganism on the skin, such as acne and others. In addition, these oils contain all the essential vitamins, minerals and fatty acids capable of providing optimal nutrition to the skin. Due to its disinfecting power, it acts efficiently in the pores, eliminating dermatitis and associated bacterial infections. It also contributes to the formation of vitamin D in the skin, helping to keep it young and elastic.
  • Oral Oleozon: It is indicated for treatment of intestinal Giardiasis.
  • Topical Oleozon: Fungicidal and bactericide actions. It is active against fungi, those producing superficial mycoses in humans such as Trichophyton mentagrophytes, Microsporum canis and Trichophyton rubrun. It is specifically active against Staphylococcus Aureus, Streptococcus b hemolytic group A and different species of gram-negative bacilli. Its efficacy has been shown in epidermophytosis and impetigo. Additionally, Oleozon support disinfection and healing of lesions on skin, as diabetic foot ulcer. Useful to manage fungi infections as several types of Tinea.
Partner search
Pharmaceutical products, Nutritional Supplements, Natural Products, biotechnology products( vaccine strains), Medical Equipment, Ozone generator equipment,ozonized and cosmetic oils
Short content description
Business opportunities for products ready to market in relevant territories. Representation contract for registration and commercialization. International economic association agreement. Cooperated production agreement. Joint venture for manufacturing, registration and commercialization and Partners to invest in increasing production capacities and new cosmetic production plants.
The programme is co-financed by the Slovenian Enterprise Fund and the European Union, namely from the European Fund for Regional Development. It is carried out on the basis of the Substantial Support of Fund Recipients (SME) programme from 2018 to 2023 within the framework of the Operational Programme for the Implementation of European Cohesion Policy from 2014 to 2020.